Why the study?
Does inhibition of platelet adhesion with anti-VWF monoclonal antibody 82D6A3 reduce neointima formation in a baboon model of in-stent stenosis?
Population
Baboon model of in-stent stenosis
Comparison
Anti-von Willebrand factor monoclonal antibody… vs Control group receiving standard treatment with…
Design
Preclinical
Authors
Loading...
Early anti-VWF therapy shows no neointima benefit in baboons; leaves open longer-term or human efficacy for in-stent restenosis.
Does inhibition of platelet adhesion with anti-VWF monoclonal antibody 82D6A3 reduce neointima formation in a baboon model of in-stent stenosis?
Inhibition of the VWF-collagen interaction with 82D6A3 does not prevent neointima formation or in-stent restenosis in a clinically relevant non-human primate model.
Badenhorst et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: